Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab

Figure 2

Right eye. In vivo imaging of parafoveal surface macrophages and the underlying microvasculature pre- (top row) and post-teprotumumab treatment (bottom row), using clinical OCT. (a) and (d) OCT-R slab located 3 μm above the ILM surface shows the presence of macrophages. Red arrows indicate the presence of surface macrophages where significant differences in cell density and/or morphology can be seen. (b) and (e) Overlay of surface macrophages and corresponding OCT-A full vascular layer. (c) and (f) Overlay of macrophage density map and OCT-A. Surface macrophage density decreased as the inflammatory burden decreased with teprotumumab treatment.